Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,934.00-1.36%ETH$2,406.06-2.96%GOLD$4,384.50+1.19%OIL$103.82-1.90%
Smart Investors Daily
BG

NASDAQ · BGMS

Bio Green Med Solution, Inc.

Healthcare · Medical - Pharmaceuticals

$1.05

Up+$0.16 (+17.30%)

Updated Sep 16, 2026, 11:35 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.95M
P/E ratio
-0.21
Dividend yield
0.00%
52-week range
$0.57 – $2.80
Volume
532.2K
Avg. volume
504.43K

Price performance

BGMS price history

1M range · 20 trading sessions · Daily adjusted prices

BGMS closed at $1.05 after 20 trading sessions, up 15.41% for the selected period.

Last close
$1.05
Period change
+15.41%
Period low
$0.83
Period high
$1.05
Daily close
View OHLC price history
BGMS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$0.8356$1.18$0.82$1.0529532.2K
Sep 14, 2026$0.8509$1.16$0.6967$0.89762.68M
Sep 11, 2026$0.852$0.873$0.8451$0.87217.5K
Sep 10, 2026$0.8704$0.8704$0.8451$0.84514.97K
Sep 9, 2026$0.8628$0.883$0.8401$0.85518.42K
Sep 8, 2026$0.88$0.88$0.8559$0.8738.22K
Sep 4, 2026$0.903$0.9035$0.8712$0.903528.81K
Sep 3, 2026$0.8743$0.93$0.8701$0.921619.44K
Sep 2, 2026$0.8499$0.8499$0.83$0.832618.15K
Sep 1, 2026$0.86$0.8707$0.85$0.8520.36K
Aug 31, 2026$0.88$0.892$0.86$0.8657.61K
Aug 28, 2026$0.8904$0.9042$0.86$0.8622.58K
Aug 27, 2026$0.8739$0.9132$0.8739$0.890612.8K
Aug 26, 2026$0.853$0.899$0.851$0.887522.68K
Aug 25, 2026$0.903$0.903$0.877$0.877125.44K
Aug 24, 2026$0.8755$0.8828$0.8655$0.87055.69K
Aug 21, 2026$0.86$0.90$0.86$0.865116.66K
Aug 20, 2026$0.9186$0.922$0.8701$0.875310.08K
Aug 19, 2026$0.91$0.9344$0.8713$0.905312.6K
Aug 18, 2026$0.881$0.9492$0.8704$0.91237.64K

Latest BGMS news

The latest Smart Investors Daily articles mentioning BGMS.

Stock researchCompany · Overview

BGMS research

Overview

Company profile and research snapshot.

Company profile

Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Firstborn Top Capital, a Licensed Private Financing Company in Malaysia, to Become Publicly Traded Via Business Combination with ARC Group Acquisition I Corp

~ Transaction values Firstborn Top Capital at pro forma enterprise value of approximately $1,091.2 million ~~ Firstborn Top Capital is a licensed private financing company committed to providing responsible, transparent and accessible financial solutions to individuals and businesses across Malaysia ~~ Executive Director, Ow Ruey Shen, will continue to lead Firstborn Top Capital ~~ Transaction provides Firstborn Top Capital the capital to accelerate growth throughout Malaysia, then Southeast Asi

Benzinga · Jul 27, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By